Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

Por van den Bent, Martin J.
Publicado em 2010

Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma

Por van den Bent, Martin J.
Publicado no Neuro Oncol (2014)

Are we done with dose-intense temozolomide in recurrent glioblastoma?

Por van den Bent, Martin J., Taal, Walter
Publicado em 2014

Current treatment of low grade gliomas

Por van den Bent, Martin J., Snijders, Tom J., Bromberg, Jacoline E. C.
Publicado em 2012

AT-34 CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA

Por Kros, Johan M., French, Pim, van den Bent, Martin J., Gorlia, Thierry
Publicado em 2014

Pros and cons of current brain tumor imaging

Por Ellingson, Benjamin M., Wen, Patrick Y., van den Bent, Martin J., Cloughesy, Timothy F.
Publicado em 2014

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

Por van den Bent, Martin J., Vogelbaum, Michael A., Wen, Patrick Y., Macdonald, David R., Chang, Susan M.
Publicado em 2009

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients

Por Draaisma, Kaspar, Wijnenga, Maarten M. J., Weenink, Bas, Gao, Ya, Smid, Marcel, Robe, P., van den Bent, Martin J., French, Pim J.
Publicado no Acta Neuropathol Commun (2015)

A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)

Por Rampling, Roy, Sanson, Marc, Gorlia, Thiery, Lacombe, Denis, Lai, Christina, Gharib, Myriam, Taal, Walter, Stoffregen, Clemens, Decker, Rodney, van den Bent, Martin J.
Publicado em 2012

AT-17 RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY...

Por Chinot, Olivier L., Wick, Wolfgang, van den Bent, Martin J., Mason, Warren, Henriksson, Roger, Saran, Frank, Nishikawa, Ryo, Revil, Cedric, Kerloeguen, Yannick, Cloughesy, Timothy
Publicado em 2014

QOL-27 PREVALENCE OF CHANGES IN PERSONALITY AND BEHAVIOR IN ADULT GLIOMA PATIENTS: A SYSTEMATIC REVIEW

Por Zwinkels, Hanneke, Dirven, Linda, Vissers, Thomas, Habets, Esther J.J., Vos, Maaike J., Reijneveld, Jaap C., van den Bent, Martin J., Taphoorn, Martin J.B.
Publicado no Neuro Oncol (2015)

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

Por Groenendijk, Floris H., Taal, Walter, Dubbink, Hendrikus J., Haarloo, Cathleen R., Kouwenhoven, Mathilde C., van den Bent, Martin J., Kros, Johan M., Dinjens, Winand N. M.
Publicado em 2010

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project

Por Bromberg, Jacoline E., Doorduijn, Jeanette K., Illerhaus, Gerald, Jahnke, Kristoph, Korfel, Agniezka, Fischer, Lars, Fritsch, Kristina, Kuittinen, Outti, Issa, Samar, van Montfort, Cees, van den Bent, Martin J.
Publicado em 2013

Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix–associated gene modules

Por Balvers, Rutger K., Kleijn, Anne, Kloezeman, Jenneke J., French, Pim J., Kremer, Andreas, van den Bent, Martin J., Dirven, Clemens M. F., Leenstra, Sieger, Lamfers, Martine L. M.
Publicado em 2013

BMET-35 CERITINIB IN ALK+ NSCLC METASTATIC TO BRAIN AND/OR LEPTOMENINGES: THE ASCEND-7 STUDY

Por Wen, Patrick Yung, Barlesi, Fabrice, Bertino, Erin M., Kim, Dong-Wan, van den Bent, Martin J., Wakelee, Heather, Arratia, Pilar Cazorla, Shen, Junwu, Branle, Fabrice, Chow, Laura Q.
Publicado no Neuro Oncol (2015)

New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III...

Por Gorlia, Thierry, Wu, Wenting, Wang, Meihua, Baumert, Brigitta G., Mehta, Minesh, Buckner, Jan C., Shaw, Edward, Brown, Paul, Stupp, Roger, Galanis, Evanthia, Lacombe, Denis, van den Bent, Martin J.
Publicado em 2013

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

Por Franceschi, Enrico, Stupp, Roger, van den Bent, Martin J., van Herpen, Carla, Laigle Donadey, Florence, Gorlia, Thierry, Hegi, Monika, Lhermitte, Benoit, Strauss, Lewis C., Allgeier, Anouk, Lacombe, Denis, Brandes, Alba A.
Publicado em 2012

Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report

Por Grisariu, Sigal, Avni, Batia, Batchelor, Tracy T., van den Bent, Martin J., Bokstein, Felix, Schiff, David, Kuittinen, Outi, Chamberlain, Marc C., Roth, Patrick, Nemets, Anatoly, Shalom, Edna, Ben-Yehuda, Dina, Siegal, Tali
Publicado em 2010

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

Por Taal, Walter, Segers-van Rijn, Joyce M. W., Kros, Johan M., van Heuvel, Irene, van der Rijt, Carin C. D., Bromberg, Jacoline E., Sillevis Smitt, Peter A. E., van den Bent, Martin J.
Publicado em 2012

Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study

Por Koekkoek, Johan A F, Kerkhof, Melissa, Dirven, Linda, Heimans, Jan J, Postma, Tjeerd J, Vos, Maaike J, Bromberg, Jacoline E C, van den Bent, Martin J, Reijneveld, Jaap C, Taphoorn, Martin J B
Publicado no BMC Neurol (2014)